Sana Biotechnology
188 East Blaine Street, Suite 400
Seattle, WA 98102
United States
Website: https://sana.com/
Email: contact@sana.com
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a team of 320 plus scientists, engineers, clinicians and biotechnology veterans creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
74 articles with Sana Biotechnology
-
CEOs at Sana Biotechnology and BioLife Solutions explain how being based in the BioForest region helped them be voted one of BioSpace's best places to work in 2023.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
11/14/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it has been named the top place to work on the BioSpace 2023 Best Places to Work small employer list.
-
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
11/3/2022
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.
-
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
11/2/2022
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2022.
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
Sana Biotechnology to Present at September 2022 Investor Conferences
9/9/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentations at two investor conferences in September.
-
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
-
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech's most exciting hotbeds.
-
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
8/4/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the second quarter 2022.
-
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
6/17/2022
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward developmen
-
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
6/13/2022
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will present data from its hypoimmune platform at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.
-
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
6/7/2022
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022.
-
Seattle-based Sana Biotechnology is moving on from its current Fremont, California manufacturing facility, inking a lease deal to develop a manufacturing plant in Bothell, Washington.
-
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory
6/1/2022
Sana Biotechnology, Inc. announced that the company has entered into a lease agreement to develop an approximately 80,000 square foot manufacturing facility in Bothell, Washington.
-
This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.
-
Dr. Terry Fry, M.D., a leader in chimeric antigen receptor T-cell (CAR-T) therapies and senior vice president, head of T-cell therapeutics at Sana Biotechnology, will be heading the newly created Gates Institute.
-
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
5/12/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute.
-
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
5/10/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the first quarter 2022.
-
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
5/4/2022
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m. PT on Wednesday, May 11, 2022.